轻至重度肝损伤对Sonidegib药代动力学的影响:多中心开放标签平行组研究
本研究为I期多中心开放标签平行组研究,比较单次口服800 mg Sonidegib在肝功能损害受试者与健康受试者中的药代动力学。结果显示,轻、中、重度肝损伤组的Sonidegib暴露量相似或降低,蛋白结合不受肝功能影响,未发现特定PK参数与肝功能参数间的明显相关,且药物总体耐受良好。结论认为轻至重度肝损伤患者无需调整剂量。
要点
- 轻至重度肝损伤患者Sonidegib暴露量相似或降低,无需调整剂量。
- 蛋白结合不受肝功能影响,游离药物与代谢物PK趋势相似。
- 特定PK参数与肝功能指标间仅弱相关或无相关。
核心结论
- 与正常组相比,轻、中、重度肝损伤组的Sonidegib暴露量相似或降低,无需调整剂量。
- Sonidegib在所有受试者中总体耐受良好。
研究设计与样本
- I期、多中心、开放标签、平行组研究,共33例受试者接受单次口服800 mg Sonidegib。
- 主要目的为比较肝功能损害受试者与健康受试者中Sonidegib的药代动力学。
主要发现
- 所有组给药后血浆浓度峰值时间约为2-3小时。
- 与正常组相比,AUClast在轻度、重度肝损伤组分别降低35%和23%,在中度肝损伤组增加14%。
- 与正常组相比,Cmax在轻度、中度、重度肝损伤组分别降低20%、21%和60%。
- 蛋白结合不受肝功能影响,游离Sonidegib及代谢物的PK参数趋势相似。
- 特定PK参数与肝功能参数之间呈弱相关至无相关。
临床怎么用
- 基于本研究结果,轻、中、重度肝损伤患者使用Sonidegib时无需进行剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Sonidegib is a potent, selective and orally bioavailable inhibitor of the Hedgehog signaling pathway, primarily metabolized by the liver. In order to make dose recommendations for patients with hepatic impairment, we have assessed here the pharmacokinetics (PKs) and safety of sonidegib in subjects with varying degrees of hepatic function. METHODS: The primary objective of this phase I, multicenter, open-label study was to evaluate the PKs of a single oral 800 mg dose of sonidegib in subjects with impaired hepatic function compared with healthy subjects. PK parameters (e.g. area under the concentration-time curve from time zero to infinity [AUCinf], area under the concentration-time curve from time zero to the last measurable concentration [AUClast], maximum concentration [C max], apparent clearance [CL/F], and terminal half-life [t ½]) for parent drug and the metabolite were compared with the normal group, as the reference. Metabolite ratio, unbound PK parameters, and the relationship between specific PK parameters and liver function parameters were assessed. RESULTS: In total, 33 subjects entered the study and received sonidegib. Plasma concentrations peaked at approximately 2-3 h in all groups after dosing. Compared with the normal group, AUClast decreased by 35 and 23% and increased by 14% in the mild, severe, and moderate hepatic impairment groups, respectively. The C max values were lower in all groups with respect to the normal group (decreases of 20, 21 and 60% in the mild, moderate and severe hepatic impairment groups, respectively). Protein binding was independent of hepatic function, and similar trends in the PK parameters were observed for unbound sonidegib and the metabolite. Protein binding was similar across all groups. Weak to no correlation between specific PK and hepatic function parameters was found. CONCLUSIONS: Overall, sonidegib exposures were similar or decreased in the hepatic impairment groups compared with the normal group, and sonidegib was generally well-tolerated in all subjects. Dose adjustment is not considered necessary for subjects with mild, moderate, or severe hepatic impairment.
引用
- Horsmans Y, Zhou J, Liudmila M, et al. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study. Clin Pharmacokinet. 2018. PMID: 28577129. doi:10.1007/s40262-017-0560-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。